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1. Introduction 
In prostate cancer patients, the use of hormonal-deprivation (HD) therapies, such as the 
gonadotrophin-releasing hormone analogues (GnRHa) or luteinizing hormone releasing 
hormone analogues (LHRHa), antiandrogens, or bilateral orchiectomy, induces a range of 
hormone-related symptoms. Hot flashes (HF) are one of most common and distressing 
symptoms that can occur. Other signs and symptoms caused by estrogen and androgen 
deprivation are metabolic syndrome, increased cardiovascular risk, loss of libido, erectile 
dysfunction, accelerated osteopenia/osteoporosis, increased bone fractures, neurocognitive 
dysfunction, weight gain, decreased muscle mass, etc. 
Since the pioneering studies by Huggins and Hodges (Huggins & Hodges, 1941), hormonal 
manipulation in which tumor cells are deprived of hormonal steroids has gained increasing 
relevance in the treatment of some types of cancer. They reported episodes of HF in 9 of 21 
castrated patients 2 to 3 weeks after surgery (Huggins & Hodges, 1941). 
Surgical castration, the most commonly used procedure to obtain HD a few years ago, has 
been gradually replaced by medical castration with the addition of LHRHa. After 
orchiectomy, approximately 50% of the patients experienced HF within months (Charig & 
Rundle, 1989; Maatman et al., 1985; Aksel et al., 1976; Buchholz & Matarelli, 1994).  
The incidence of HF is 60-75% with the use of LHRHa (Harvey et al., 1985; Leuprolide Study 
Group, 1984; Sarosdy et al., 1999; Parmar et al., 1987). The reason why this incidence rate is 
higher than that observed with surgical removal is not well understood. As is the case with 
orchiectomy, HF occur over several months and may persist, although with less intensity, 
for many years. 
Hot flashes are a major clinical problem in many cancer patients undergoing HD (Charig & 
Rundle, 1989; Nishiyama et al., 2004; J. S. Carpenter et al., 2004), as demonstrated by the 
quality of life studies. 
While HF are not considered a serious adverse effect, their frequency and severity may be 
bothersome and can impair patients’ quality of life. Thus we need to understand the 
mechanism of hot flashes and use this information to develop patient-tailored therapies to 
address these symptoms.  
The purpose of this chapter is to discuss theories, to observe how they are reflected in the 
pathophysiology of HF, and to describe current treatments. 
2. Pathophysiology  
Hot flashes are characterized by a subjective sensation of heat perceived mainly in the upper 
part of the chest, followed by excessive perspiration. The major symptom is the subjective 
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feeling of heat which may last several (4 to 10) minutes, and may be associated with other 
clinical complaints such as anxiety, irritability, palpitations, blushing, panic, and a sensation 
of loss of control, along with significant physical and emotional distress (Albertazzi, 2006). 
A mean rise of 0.9º C in body temperature is detected between 7 and 20 minutes before the 
hot flashes, with an ensuing increase in both the energy expenditure and the respiratory 
quotient (J. S. Carpenter et al., 2004).  
Generalized peripheral vasodilatation typically appears within the first seconds of the 
episode (Molnar, 1975; F. L. Kronenberg et al., 1984). In addition, an increase in sweating 
and electric conductance are observed, with a strong correlation between both parameters 
(Molnar, 1975). During a HF a 30-second rise of 2-S in skin conductance occurs (Robert R 
Freedman, 2005; J. S. Carpenter et al., 1999). Independently of the patient’s perception, the 
measurement of skin conductance might be used for the clinical monitoring of HF, since it 
can be recorded on an outpatient basis by means of a Holter-like system. In such cases, a 
close correlation exists between these recordings and those obtained from daily data-
collection questionnaires (Robert R Freedman, 2005; J. S. Carpenter et al., 1999).  
There are many hypotheses about the mechanism of HF (Figure 1). We will proceed to 




Fig. 1. Different hypotheses on the mechanism of hot flashes  
2.1 Gonadal hypothesis 
Since HF are commonly associated with orchiectomy in men and with menopause and 
ovarian failure in women, it may be assumed that they are causally related to low sex 
hormone levels.  
It is necessary to remember that estrogens come from androgens. Aromatase cytochrome 
P450 is the enzyme that is responsible for estradiol biosynthesis from testosterone. 
The hormone deprivation theory applied to prostate and breast carcinoma patients seems 
appealing and is based on the occurrence of HF following both medical and surgical 
castration. The responses to hormone replacement therapy and the effects following its 
withdrawal further support this hypothesis. However, an argument against this hypothesis 
is the absence of HF in patients with congenital hypogonadism (Turner and Kallman 
syndromes) as well as in prepubertal children (Kouriefs et al., 2002). These scenarios suggest 
that HF result from the dynamic reduction or sudden deprivation of sex hormones rather 
than their absolute plasma concentration. The Dynamic hypothesis is currently the most 
widely accepted theory (Kouriefs et al., 2002). 
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2.2 Pituitary hypothesis 
In 1976, Alksel (Aksel et al., 1976) argued against the deprivation hypotheses. After 
suggesting that HF occurred due to a rise in gonadotrophin levels, he postulated a pituitary 
rather than a gonadal cause for this phenomenon. His theory is supported by studies 
performed on premenopausal women in whom a correlation was found between HF and 
the levels of both luteinizing hormone (LH) and follicle-stimulating hormone (FSH) 
(Melldrum et al., 1984). Casper (Casper et al., 1979) and Tataryn (Tataryn et al., 1979) 
demonstrated a synchrony between LH peaks and HF, which led them to propose a 
pulsating hypothesis. However, it must be noted that LH surges are not consistently 
associated with HF, although all hot flash episodes do coincide with an LH peak. 
2.3 Hypothalamic hypothesis 
In postmenopausal women, no correlation has been seen between gonatropin levels and HF 
(Linsell & Lightman, 1983). Also to be noted is the absence of HF in patients with Klinefelter 
syndrome in whom constitutively high gonadotrophin levels are found, and in other treated 
patients with high induced gonadotrophin levels (such as those used in ovulation-inducing 
protocols). HF does appear, however, after a hypophysectomy and during the LHRHa 
therapy for prostate cancer.  
As a result of these findings, many investigators have suggested a potential role for the 
hypothalamus in the pathophysiology of HF (Kouriefs et al., 2002).  
The similarities between HF and adrenergic symptoms have led to theories regarding the 
potential involvement of catecholamines (Albertazzi, 2006) in the hypothalamic hypothesis. 
After failing to show a correlation between HF and peripheral catecholamine levels, Casper 
(Casper et al., 1979) postulated the involvement of central pathways. On the other hand, 
some evidence points to noradrenaline (NA) as the hypothalamic neurotransmitter 
responsible for HF. Animal experiments have shown that the intrahypothalamic 
administration of NA affected thermoregulation (Albertazzi, 2006). Furthermore, high 
peripheral concentrations of MHPG (3-methoxy-4-hydroxiphenylglycol) — the major brain 
NA metabolite— during HF were found, while no changes in VMA (vanilmandelic acid) —a 
peripherally produced NA metabolite— were seen (R R Freedman, 2001).  
Additional evidence to support this catecholaminic hypothesis (Figure 1) is the finding that 
the administration of yohimbine (an ǂ2-adrenergic antagonist) to symptomatic women 
increases hypothalamic NA concentrations and induces HF that subside after administration 
of clonidine (an ǂ2-agonist) (R R Freedman et al., 1990). The increased sympathetic 
activation, mediated by the ǂ2-adrenergic receptor, plays a major role in the occurrence of 
HF. Since ǂ2 receptors are modulated by estrogens, abrupt estrogen deprivation is likely to 
contribute to the development of HF via this pathway (Etgen et al., 2001). Exposure to high 
temperatures and hot drinks generates a reduction in the number of ǂ2 receptors, which is 
followed by a further release of additional amounts of NA and the appearance of HF 
(Kouriefs et al., 2002).  
On the other hand, the hypothalamic thermoregulatory center is anatomically very close to 
the LHRH producing center (de Boer et al., 2009). (Figure 2)  
Increases in hypothalamic NA caused by HD are thus likely to both stimulate LHRH 
producing neurons and activate the heat-losing mechanisms controlled by the adjacent 
thermoregulatory center (R R Freedman & Krell, 1999; Dacks & Rance, 2010). It has also been 
www.intechopen.com
 Prostate Cancer – From Bench to Bedside 
 
372 
observed that high NA levels trigger HF by lowering the sweat-flash threshold in 
symptomatic postmenopausal women (Albertazzi, 2006).  
The relation between sex steroids and hypothalamic cathecolamines remains unclear. The 
catecholestrogen (2-hydroxiestrogen) theory is based on the fact that the chemical structure 
of catecholestrogens, the most common estrogen metabolites, is similar to that of 






Fig. 2. Direct effect of noradrenaline on hypothalamic nucleus to trigger hot flash 
mechanism  
Hypothalamic catecholestrogen concentrations are ten times greater than those of estrogens. 
Catecholestrogens act on the enzymes catecholmethyltranspherase and tyrosinhydroxilase 
which, in turn, influence the synthesis and breakdown of catecholamines, thus reducing NA 
levels. Therefore, low hypothalamic catecholestrogen concentrations will result in an 
increase of NA levels and the onset of HF. (Figure 3) 
Opioids are also implicated in the pathogenesis of HF. Stubbs et al. (Stubbs et al., 1978) 
induced HF with the administration of opioids to healthy volunteers. Naloxone, an opioid 
antagonist, causes vasomotor symptoms when administered to opioid-dependent animals 
(Tulandi et al., 1985). Sex steroids induce the hypothalamic production of ǃ-endorphins, 
which are endogenous hypothalamic opioids that inhibit catecholamine synthesis by 
reducing the activity of the estrogen-2-hydroxilase (Fishman et al., 1980). Peripheral sex 
hormones promote the formation of catecholestrogens as well, which in turn block the 
hypothalamic synthesis of NA (Robert R Freedman, 2005). (Figure 3) Therefore, a sudden 
deprivation of sex hormones will result in decreased endorphin levels and loss of negative 
feedback (R R Freedman & Krell, 1999).  
The ensuing rise in hypothalamic NA levels eventually enhances the release of LHRH by the 
LHRH-secreting neurons. NA also acts on the thermoregulatory center by shortening its 
response range, lowering its temperature tolerance thresholds, and generating HF, which in 
turn enhances heat loss (Robert R Freedman, 2005; R R Freedman & Krell, 1999). (Figure 2) 
At the regulatory center, there is a zone for the control of body temperature. At the lower 
threshold, a shivering mechanism is triggered, leading to a rise in temperature. At the upper 
threshold, heat loss is induced through skin vasodilatation and profuse sweating. Between 
these two thresholds is a thermoneutral zone (Savage & Brengelman, 1996). (Figure 4) 
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Fig. 3. Negative impact of sex hormones on noradrenaline production 
 
 
Fig. 4. Body temperature control range in an asymptomatic patient 
In patients with HF, the thermoneutral zone is quite narrow, which is why small changes 
may influence the thermoregulatory center (Robert R Freedman, 2005; Dacks & Rance, 2010). 
(Figure 5) The increase in body temperature after a rise in ambient temperature or the intake 
of excessively hot food exceeds the upper threshold of the thermoneutral zone and triggers 
the heat-dissipating mechanisms (Dacks & Rance, 2010; Savage & Brengelman, 1996).  
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Fig. 5. Body temperature control range in symptomatic patient 
The increase in hypothalamic levels of certain substances, such as noradrenaline, tends to 
narrow this zone, while other agents such as serotonin and dopamine have the opposite effect 
(Berendsen, 2000). (Figure 6) It has been concluded that the thermoneutral zone is 0.4 ºC in 
asymptomatic and 0.0 ºC in symptomatic patients (Robert R Freedman, 2005).  
Serotonin (5-hydroxytryptamine or 5-HT) levels are reduced in postmenopausal women, 
even though they normalize following replacement therapies.  
A sudden deprivation of sex hormones results in a reduction of circulating serotonin, with a 
parallel increase in its 5-HT2A hypothalamic receptors. These receptors may also play a role 




Fig. 6. Effect on thermoneutral zone of various substances  
To sum up, a basic feature in the pathogenesis of HF is the negative effect of plasma sex 
hormones on the hypothalamic secretion of noradrenaline, as well as its balance with 
serotonin and dopamine. (Figure 7) 
Other information supports the hypothalamic hypothesis. It has recently been demonstrated 
that serum IL-8 concentrations were significantly higher in women with HF than without 
HF. IL-8 could play an important role in the pathophysiology of HF (Yasui et al., 2006; 
Noguchi et al., 2008). 
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Fig. 7. Negative effect of sex hormones on hypothalamic noradrenaline 
The rat ortholog of the human IL-8 receptor has been identified (Dunstan et al., 1996), and 
the functions of IL-8 appear to be performed by cytokine-induced neutrophil 
chemoattractant (CINC) in rodents (Guex-Crosier et al., 1996). It has been shown that CINC 
stimulates the secretion of prolactin, GH, and ACTH but suppresses the secretion of LH and 
FSH from the anterior pituitary cells (Koike et al., 1994). In animal models HF could be 
triggered by intracerebroventricular injection (i.c.v.) of LHRH analogues (Noguchi et al., 
2008; Noguchi et al., 2003). After that, an increase of CINC around the periventricular area 
in the hypothalamus is observed in ovariectomized rats. 
Hypothalamic thermoregulation by CINC and LHRH may, therefore, be a reciprocal 
relationship. However, changes in CINC concentration and skin temperature after i.c.v. 
injection of LHRHa were reversed by replacement of estradiol. Therefore, there may be a 
feedback regulation mechanism involving LHRH and CINC through the hypothalamus-
pituitary-gonadal axis (Noguchi et al., 2008). 
Consequently, LHRH and CINC play a key role in the homeostasis of body temperature in 
HD situations (Noguchi et al., 2008). All these finding support the hypothalamic 
hypothesis. 
New aspects of hot flash research, including neuroimaging and the study of genetic 
polymorphisms, when combined with increasingly nuanced ways of asking questions of 
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culturally distinct populations, pose challenges, but at the same time offer a rich complexity 
from which a better understanding of hot flashes will emerge (F. Kronenberg, 2010). 
Other parts of the brain can be seen to be involved in the development of hot flashes. 
Magnetic resonance imaging has shown activation of the insula and anterior cingulated 
cortex during hot flash episodes (F. Kronenberg, 2010).  
Finally, genetic variation in CYP19 and sex hormone binding globulin contributes to 
variance in circulating hormone levels between postmenopausal women, and it could 
potentially have an influence on hot flashes (Dunning et al., 2004). 
3. Current treatment of hot flashes 
As is to be expected, the great majority of published studies were carried out in menopausal 
women or in breast cancer survivors, but more and more trials are being conducted in 
patients undergoing hormone deprivation for prostate cancer. 
In view of their pathophysiology, the regulatory mechanisms on negative feedback should 
be taken into account as causes of these hot flashes. 
3.1 Hormone replacement 
Hormone replacement with estrogens was the first treatment used in the 20th century. Other 
forms of replacement included progesterones and androgens, but because of the hormone 
sensitivity of prostate cancer, the latter would be contraindicated. 
As for estrogens, it should be noted that despite their high efficacy even at low doses, they 
have negative side effects. These include thromboembolic phenomena, cardiovascular 
morbidity and painful gynecomastia (J. A. Smith, 1994; J. I. Miller & Ahmann, 1992; Atala 
et al., 1992). 
The most widely used estrogen, both orally and transdermally, is estradiol (Shanafelt et al., 
2002), which requires at least a month to obtain benefits. Higher doses provide better control 
of symptoms than lower doses but also have more side effects, though these are fewer when 
transdermal formulations are used. The usual oral doses are ≥ 0.25 mg/day, whereas the 
daily amount required for patches is less than 0.05 mg/day. 
In summary, estrogen therapy shows a dose-dependent response, with a balance in favor of 
transdermal therapy and an efficacy of 80-90%, reducing the number of hot flashes by 2.5 to 
3 hot flashes daily (Rossouw et al., 2002; Nelson, 2004), but with undesirable side effects that 
need to be considered (Kouriefs et al., 2002; Rossouw et al., 2002). Its effectiveness was 
confirmed in a 2002 meta-analysis from the Cochrane Library, in an extensive review 
published in JAMA in 2004 (Nelson, 2004), and in a more recent systematic review in Lancet 
Oncology (Frisk, 2010). 
Progesterones, like estrogens, stimulate the production of hypothalamic ǃ-endorphins. Their 
use is also not free from undesirable side effects (C L Loprinzi et al., 1994; Quella et al., 1998; 
C L Loprinzi et al., 1992). There is experience in both men and women, and the most used is 
megestrol acetate, with starting doses of 20 mg twice daily and subsequent reduction to the 
lowest effective dose, with response rates of 80-90% (Frisk, 2010; J. W. Goodwin et al., 2008; 
Quella et al., 1998; C L Loprinzi et al., 1994). 
As a second drug in use, cyproterone acetate is a steroidal antiandrogen with progestogenic 
action. It shows response rates comparable to megestrol acetate but with risk of hepatoxicity, 
fatigue, painful gynecomastia and galactorrhea (Frisk, 2010). Treatment for hot flashes should 
be started at 50 mg/day, and not exceed 300 mg/day (Moon, 1985; Irani et al., 2010). 
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Lastly, we need to mention medroxyprogesterone acetate given in 20-40 mg oral doses daily 
with equal or superior efficacy to megestrol or a single 400 mg i.m. depot dose with an effect 
sustained over at least 6 months (Irani et al., 2010; Prior et al., 1995). Although some experts 
consider 400 mg to be a very high dose, it is a small dose if we compare it to the 500 mg 
intramuscular or oral doses used daily during months for the treatment of breast cancer. It 
was found to be correctly tolerated and weight gain was the only undesirable effect. 
There have been reservations regarding the use of progesterones in prostate cancer because 
it has been reported in some articles to be related to increases in PSA levels (Dawson & 
McLeod, 1995; Wehbe et al., 1997). Clarification is still required before these results can be 
extrapolated to support the use of low-dose progesterones in the treatment of prostate 
cancer, although their antitumor activity has also been reported in breast, endometrium and 
prostate cancer (Wentz, 1985; Bonomi et al., 1985). 
The effect of estrogens and progesterones can persist for extended periods after their 
withdrawal (C L Loprinzi et al., 1994; Haas et al., 1988). 
The problems of the use of hormone replacement therapy in menopausal women have 
acquired a certain prominence as a result of the publication of the results of the Women´s 
Health Initiative randomized controlled trial, which reveal the increased risk of developing 
breast cancer, cognitive disorders, cardiovascular and thromboembolic disease. Alternative 
treatments are therefore desirable. 
The absolute risks per 10,000 person-years were 7 more coronary events, 8 more strokes, 8 
more pulmonary embolisms, and 8 more invasive breast cancers, while absolute risk 
reductions per 10,000 person-years were 6 fewer colorectal cancers and 5 fewer hip 
fractures. They also reduced vasomotor symptoms and vulvovaginal atrophy (G. L. 
Anderson et al., 2004). 
3.2 Non-hormonal therapies 
The current availability of non-hormonal therapies is a major advance both for women who 
have survived breast cancer and for men with a prostate adenocarcinoma undergoing 
hormone deprivation, in whom hormone replacement therapy may be contraindicated due 
to adverse effects.  
Several drugs have been tested for the management of vasomotor symptoms. A 2006 meta-
analysis of well-designed studies (Nelson et al., 2006) showed that the only effective 
therapies are, in increasing order of effectiveness: gabapentin, selective serotonin-reuptake 
inhibitors, and clonidine. A brief description of these therapies is discussed below. Their 
efficacy is slightly less than with hormone replacement, but their effectiveness has been 
widely demonstrated. 
Since noradrenaline is the neurotransmitter involved in the control of the thermoregulatory 
center, the blockade of both ǂ- and ǃ-adrenoceptors may provide symptomatic relief. On 
this basis, the ǂ2 agonist clonidine (Clayden et al., 1974) has been tested in both men and 
women (Pandya et al., 2000). Alpha2 receptors have been identified at both hypothalamic 
and peripheral levels. Their presynaptic activation brings about a decrease of NA release (R 
R Freedman & Dinsay, 2000). They are also peripherally active by reducing vasodilatation, 
which contributes to improved control of hot flashes (Kouriefs et al., 2002). Although higher 
doses are associated with a more significant symptomatic relief, they also involve a greater 
toxicity. Transdermal administration (Nagamani et al., 1987) results in equivalent absorption 
to oral administration, but is associated with more common skin reactions. Recommended 
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doses are between 25 to 400 μg. Its efficacy is lower than that of hormonal therapy (20-55%), 
and side effects are common. Two recent double-blind randomized-controlled clinical trials 
and a systematic review, comparing clonidine to venlafaxine, have reported conflicting 
results (Frisk, 2010; Buijs et al., 2009; Loibl et al., 2007). The drug may be potentially useful 
when other therapies are contraindicated (Kouriefs et al., 2002). 
Response rates of 44-60% have been achieved with gabapentin 300 mg every 8 hours, with 
the main side effects being somnolence, dizziness, fatigue, skin rash, palpitations, and 
peripheral edema (Charles L Loprinzi et al., 2007; C L Loprinzi et al., 2009). In a recent open-
label, randomized, cross-over trial gabapentin is worse tolerated than Venlafaxine 
(Bordeleau et al., 2010). 
Its mechanism of action, although at present unclear, may involve the modulation of 
calcium channels (T. J. Guttuso, 2000). In a recent study, gabapentin has been shown to be 
useful in patients with an inadequate response to antidepressants (Charles L Loprinzi et 
al., 2007). 
Some serotonin-acting antidepressants may be of value in the management of hot flashes. 
As mentioned above, serotonin levels, which are decreased in postmenopausal women, tend 
to normalize after replacement therapies. Thus, an abrupt fall in sex hormones is likely to 
produce a decrease in circulating serotonin along with an up-regulation of their 5-HT2A 
hypothalamic receptors (Albertazzi, 2006; Curcio et al., 2005), which may be involved in the 
pathogenesis of hot flashes.  
The potency of 5-HT2A antagonists varies widely among the first generation (tricyclic) 
antidepressants, although the resulting impact on the therapeutic activity of these drugs has 
not yet been defined. Another class of antidepressants, known as phenylpiperazines, has 
been shown to be more selective than tricyclics and to possess more potent 5HT2A receptor-
blocking activity. 
Newer antidepressants, mainly venlafaxine, desvenlafaxine and paroxetine, play an 
important role in the non-hormonal therapy of hot flashes (Albertazzi, 2006). Observed 
response rates are approximately 50-69 %, somewhat lower than those achieved with 
hormonal therapies; however, their improved safety profile in cancer survivors makes them 
an appealing option for this group of patients. Serious side effects are rare, since the doses 
used are lower than those normally given for the treatment of depression, and a withdrawal 
syndrome has not been associated with such doses (Irani et al., 2010; Buijs et al., 2009; Loibl 
et al., 2007; C L Loprinzi et al., 2000; Archer et al., 2009). 
There is little data regarding the use of new-generation antidepressants for the treatment of 
hot flashes in prostate cancer patients undergoing hormone deprivation. Venlafaxine has 
been shown to produce symptomatic relief in a study involving 16 patients (Quella et al., 
1999). Another small study with 24 patients reported symptomatic relief of hot flashes in 
men who received paroxetine for 5 weeks (Charles L Loprinzi et al., 2004). (Table 1)  
However, the use of selective reuptake inhibitors such as paroxetine during tamoxifen 
treatment must be evaluated with caution, as it is associated with an increased risk of death 
from breast cancer. This could be due to the inhibition of the cytochrome P450 2D6 
(CYP2D6) pathway (Kelly et al., 2010). 
Another interesting antidepressant is trazodone, a triazolopiridine-derived phenylpiperazine. 
Trazodone is a potent and selective postsynaptic antagonist of the 5-HT2A receptor as well as a 
moderate inhibitor of serotinin reuptake (Pansini et al., 1995). It belongs to a class of 
antidepressants called SARI (serotonin 2A agonist and reuptake inhibitors). Trazodone 
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shows a high affinity for 5-HT2A receptors, along with a moderate affinity for 5-HT1A 
receptors. (Figure 8) 
 
Paroxetine doses between 10 and 25 mg/day, with 60-65 % response rates 
Venlafaxine 
25 or 37,5 mg/day increased to 75 mg/day after 1 week, with 
response rates of 50-65 %. 
Desvenlafaxine 150 mg/day, with response rates of 51-69 %. 
Fluoxetine doses of 20 mg/day, with an effectiveness of about 50%. 
Citalopram 
20 mg/day, with an effectiveness of about 50%. (Suvanto-
Luukkonen et al., 2005; Debra L Barton et al., 2010) 
Veralipride antidopaminergic drug 
Sertraline 50 mg/day, with a response rate of 36 % (Kimmick et al., 2006). 
Table 1. Dosages and response rates for selected antidepressants 
Conversely, a traditional selective serotonin reuptake inhibitor (SSRI), such as fluoxetine, 
has little affinity for 5-HT1A and 5-HT2A receptors, even though its potency to inhibit 
serotonin reuptake is greater than that of trazodone. In fact, the concentration of drug 
needed to produce a 50% inhibition (IC50) of reuptake is only 6 nmol/l for fluoxetine and 
115 nmol/l for trazodone (Owens et al., 1997).  
 
 
Fig. 8. Trazodone action at synaptic level. 
SSRIs stimulate all types of serotonin receptors because they increase free 5-HT levels 
without blocking any receptors. Although these drugs have been useful in the treatment of 
depression, they cause adverse reactions, such as agitation, anxiety, and sexual dysfunction, 
due to the stimulation of 5-HT2A receptors in other tissues (e. g., brainstem and spinal cord) 
(Stahl, 1998). It is worth noting that 5-HT2A receptors are the main receptors associated with 
hot flashes and are inhibited by trazodone. 
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Since trazodone does not cause a clinical blockade of acetylcholine receptors, the potential 
anticholinergic effects (blurred vision, cardiac alterations, mouth dryness, intestinal 
disorders, urinary retention, and increased intraocular pressure) are negligible. Moreover, 
since it lacks any clinical effects on NA inhibition, other potential side effects such as apathy, 
lack of motivation, anhedonia, and difficulty concentrating are minimal.  
Nevertheless, trazodone shows an interesting affinity for -receptors. The high and 
moderate activity of trazodone for 1- and 2- adrenergic receptors, respectively, might 
contribute to the beneficial effects described on erectile dysfunction (Krege et al., 2000). On 
the other hand, this same property could also lead to orthostatic hypotension. 
Trazodone also blocks H1-histamine receptors (H1) and, probably due to its histamine-
blocking properties and potent 5-HT2A antagonist activity (Stahl, 1998; Marek et al., 1992), 
also exhibits a sedative activity that has been shown to be useful for the treatment of elderly 
patients with agitation and insomnia. 
Because of its pharmacological profile, this antidepressant may be valuable in the treatment 
of hot flashes in prostate cancer patients undergoing hormone deprivation. 
As mentioned above, NA acts on the thermoregulatory center by shortening its response 
range and lowering its tolerance threshold, which in turn results in cutaneous vasodilation 
and profuse sweating. Drugs with noradrenergic properties, which could trigger the onset 
of hot flashes, should thus not be used in prostate cancer patients undergoing hormone 
deprivation. Furthermore, while NA shortens the thermoregulatory response range, 
serotonin and dopamine have an opposite effect. (Figure 6)  
The use of serotonergic antidepressants may be warranted and, in fact, a few of them have 
already been tested with encouraging results.  
In addition, considering that hormone deprivation is associated with low serotonin 
concentrations and stimulation of 5-HT2A receptors, some drugs, such as trazodone, whose 
pharmacological profile is characterized by a high affinity for these 5-HT2A receptors and a 
moderate effect on serotonin reuptake, might be beneficial in the management of hot flashes, 
unlike serotonergic antidepressants (SSRIs), which lack this property. This profile might also 
be significantly helpful in the control of anxiety, sleep and erectile dysfunction, all of which 
would result in a quality of life improvement. 
To date there are few studies examining the use of trazodone in hormonally deprived 
patients. One pilot study assessed the management of hot flashes in 25 menopausal women. 
No objective effect was seen after doses of 75 mg/day for 3 months, although anxiety, 
insomnia and irritability were reduced (Pansini et al., 1995). Further studies are required to 
elucidate the potential efficacy of trazodone against hot flashes by using validated scales to 
ascertain such effect.  
It should be mentioned that the placebo effect can improve hot flashes in 20-40 % of patients, 
with perceived efficacy rates of 50-75 % for initialuse (J A Sloan et al., 2001; Moyad, 2002). 
Other drugs have been shown to be either less effective or ineffective, or have been 
disregarded for the management of hot flashes because of their high incidence of side 
effects. (Table 2) 
Some dietetic measures can be helpful, namely: cold water irrigations or the application of 
cold; avoiding excessively hot food and very hot environments; limiting the consumption of 
spicy food, coffee and alcohol; following a diet rich in soy protein-containing products (the 
use of phytoestrogens, although recommended by some authors, is to be avoided because of 
its potential effect on hormonal-dependent cancer) (J A Sloan et al., 2001; Carmignani et al., 
2010); reducing stress by means of relaxation techniques like yoga ; engaging in non -
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strenuous physical exercise to maintain an appropriate weight (being overweight can 
increase both the frequency and severity of hot flashes) (Sideras & Charles L Loprinzi, 2010; 
Robert R Freedman, 2005); and quitting smoking. 
 
 Bellergal (phenobarbital + ergotamine + belladonna alkaloids), with a 30 % 
withdrawal rate from therapy due to toxicity (Bergmans et al., 1987). 
 Dietary supplements.  
 High-dose supplements of isoflavones/phytoestrogens (both estrogenic and 
antiestrogenic effects). 
 Medicinal plants (Moyad, 2002). 
 Vitamin E (Moyad, 2002). 
 Methyldopa (M. G. Hammond et al., 1984). 
 Relaxation techniques, physical exercise, acupuncture. 
 L-Isoleucine and L-Valine (T. Guttuso et al., 2008). 
Table 2. Some commonly used measures for hot flash management 
 




Estrogens Estradiol p.o. (0.25 mg/day) or transdermal (0.05 mg/day) 80-90 % 
Progesterones 
Megestrol acetate 20 mg/12 h  
Cyproterone acetate 50-100 mg/day 
Medroxyprogesterone acetate p.o. 20-40 mg/day or single 400 
mg i.m. depot dose 
80-90 % 
Clonidine 25-400 mcg/day  20-55 % 
Antidepressants
Paroxetine 10-25 mg/day  
Venlafaxine 25-75 mg/day  
Desvenlafaxine 150 mg/day 
Fluoxetine 20 mg/day  
Sertraline 50 mg/day  






Gabapentin 300 mg/8 h  44-60 % 












Table 3. Summary of all data presented 
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Acupuncture has been studied for alleviation of hot flashes in patients with prostate carcinoma 
(Harding et al., 2009) and in postmenopausal women (E. M. Walker et al., 2010). However 
more studies are needed to confirm any benefit (Sideras & Charles L Loprinzi, 2010). 
A correlation between body mass index and the frequency of hot flashes, as determined by 
insulin metabolism in fat tissues and an increase in body temperature, has been shown in 
recent studies, (Robert R Freedman, 2005; Gold et al., 2000). A relationship has also been 
reported with tobacco consumption, which might be explained by an effect on estrogen 
metabolism or a thermogenic action of nicotine, (Robert R Freedman, 2005; Whiteman et al., 
2003; Jessen et al., 2003) 
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